Author(s)

Wei Xiao ¹, Mao Ye ¹, Jing Huang ¹, Yun Cao ¹, Xihong Cao ¹

Affiliation(s)

¹ Sichuan Science City Hospital, Mianyang, Sichuan, 621000, China

Corresponding Author

Wei Xiao

ABSTRACT

To explore its safety and efficacy for thromboprophylaxis of apixaban and enoxaparin after total hip arthroplasty (THA) patients. The study was designed as a prospective observational study, and all 70 patients who met the inclusion and exclusion criteria and underwent elective total hip (THA) arthroplasty between 1 January 2021 and 30 June 2022 were randomly assigned to Apixaban (Twice daily Dose 2.5 mg orally) or enoxaparin (Dose 60 mg every 24 hours subcutaneously), 35 patients were treated with apixaban and 35 patients were treated with enoxaparin. Apixaban treatment was started 12 to 24 hours after surgical wound closure and enoxaparin treatment was started 12 hours before surgery. A venogram was repeated at 42 days with postoperative prophylaxis. SPSS 28.0 was used to analyze the data, P < 0.05 was significant difference.The experiment compared the prices of them. The 70 patients included in the study were lost to follow-up due to possible reasons, and only 51 patients completed the trial in the end, including 26 patients apixaban and 25 patients enoxaparin. In studies apixaban at Dose 2.5 mg had similar to 60 mg daily and had similar bleeding characteristics. And there were no differences at 90-day. Price comparison prompts thatEnoxaparin cost more than apixaban throughout the trial period. symptomatic was lower in the apixaban group. Oral administration of apixaban showed better safety, similar efficacy, lower Price and better compliance hip arthroplasty in patients.

KEYWORDS

Apixaban, Enoxaparin, Total hip arthroplasty, Thrombus

CITE THIS PAPER

Wei Xiao, Mao Ye, Jing Huang, Yun Cao, Xihong Cao, Efficacy and Safety of Apixaban and Enoxaparin for Thromboprophylaxis after Total Hip Arthroplasty. MEDS Clinical Medicine (2024) Vol. 5: 126-131. DOI: http://dx.doi.org/10.23977/medsc.2024.050220.

REFERENCES

[1] Geerts WH, Bergqvist D, Pineo GF. Prevention of venous thromboembolism: American college of chest physicians evidence-based clinical practice guidelines (8th Edition). Chest. 2008; 133: 381S-453S.
[2] Lassen MR, Gallus A, Raskob GE, Pineo G, Chen D, Ramirez LM. Apixaban versus enoxaparin for thromboprophylaxis after hip replacement. N Engl J Med. 2010; 363(26): 2487-2498.
[3] Yijun X, Jun X, Yang Z, Zhanjun S. Progress of clinical research on anticoagulant drugs to prevent deep vein thrombosis and related complications after arthroplasty. Modern Biomedical Progress. 2016; 16(12): 2376-2379+2383.
[4] Min P, Liyan C. Efficacy and safety of apixaban against deep vein thrombosis and pulmonary embolism. Chinese journal of cardiovascular disease. 2015; 43(10): 923-926.
[5] Wong PC, Crain EJ, Xin B. Apixaban, an oral, direct and highly selective factor Xa inhibitor: in vitro, antithrombotic and antihemostatic studies. J Thromb Haemost. 2008; 6: 820-829.
[6] Feng W, Wu K, Liu Z. Oral direct factor Xa inhibitor versus enoxaparin for thromboprophylaxis after hip or knee arthroplasty: systemic review, traditional meta-analysis, dose–response meta-analysis and network meta-analysis. Thromb Res. 2015; 136(6): 1133-1144.
[7] Schulman S, Kearon C. Subcommittee on control of anticoagulation of the Scientific and standardization committee of the international society on thrombosis and haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost. 2005; 3(4): 692-694.
[8] Qinan Y, Lizhu H, Yuan B, Xuefei H, Yang L, Yujie S, et al. Interpretation of the 2021 edition of the Asia-Pacific consensus on venous thromboembolism in knee and hip arthroplasty and hip fracture surgery: Pharmacological Prophylaxis of Venous Thromboembolism. Medicine Herald. 2022; 41(05): 599-602.
[9] Gogarten W, Vandermeulen E, Van Aken H, Kozek S, Llau JV, Samama CM, et al. European scoeity of anaesthesiology, regional anaesthesia and antithrombotic agents: recommendations of the european society of anaesthesiology. Eur J Anaesthesiol. 2010; 27(12): 999-1015.
[10] Gómez-Outes A, Terleira-Fernández AI, Suárez-Gea ML, Vargas-Castrillón E. Dabigatran, rivaroxaban, or apixaban versus enoxaparin for thromboprophylaxis after total hip or knee replacement: systematic review, meta-analysis, and indirect treatment comparisons. BMJ. 2012; 344: e3675.
[11] Gómez-Outes A, Avendaño-Solá C, Terleira-Fernández AI, Vargas-Castrillón E. Pharmacoeconomic evaluation of dabigatran, rivaroxaban and apixaban versus enoxaparin for the prevention of venous thromboembolism after total hip or knee replacement in Spain. Pharmacoeconomics. 2014; 32(9): 919-936.
[12] Mihara M, Tamaki Y, Nakura N, Takayanagi S, Saito A, Ochiai S, et al. Clinical efficacy of risk-stratified prophylaxis with low-dose aspirin forthe management of symptomatic venous thromboembolism after total hiparthroplasty. J Orthop Sci. 2020; 25(1): 156-160.
[13] Thiengwittayaporn S, Budhiparama N, Tanavalee C, Tantavisut S, Sorial RM. Asia-Pacific (AP) region venous thromboembolism (VTE) consensus group, Asia-Pacific venous thromboembolism consensus in knee and hip arthroplasty and hip fracture surgery: Part 3. Pharmacological venous thromboembolism prophylaxis. Knee Surg Relat Res. 2021; 33(1): 24.
[14] Falck-Ytter Y, Francis CW, Johanson NA, Curley C, Dahl OE, Schulman S, et al. Prevention of VTE in orthopaedicsurgery patients: antithrombotic therapy and prevention of thrombosis, American college of chest physicians evidence-based clinical practice guidelines. Chest. 2012; 141(2): e278S-e325S.
[15] An VV, Phan K, Levy YD, Bruce WJ. Aspirin as thromboprophylaxis inhip and knee arthroplasty: a systematic review and meta-analysis. J Arthroplast .2016; 31(11): 2608–2616.
[16] Dager WE. Warfarin for venous thromboembolism prophylaxis after elective hip or knee arthroplasty: exploring the evidence, guidelines, and challenges remaining. Ann Pharmacother. 2012; 46(1): 79-88.
[17] Lassen MR, Raskob GE, Gallus A, Pineo G, Chen D, Hornick P, et al.ADVANCE-2 investigators. Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomized double-blind trial. Lancet. 2010; 375(9717): 807-815. 
[18] Raskob GE, Gallus AS, Pineo GF, Chen D, Ramirez LM, Wright RT, et al. Apixaban versus enoxaparin for thromboprophylaxis after hip or knee replacement: pooled analysis of major venous thromboembolism and bleeding in 8464 patients from the ADVANCE-2 and ADVANCE-3 trials. J Bone Joint Surg Br. 2012; 94(2): 257-264.
[19] Lassen MR, Davidson BL, Gallus A, Pineo G, Ansell J, Deitchman D, et al. The efficacy and safety of apixaban, an oral, direct factor Xa inhibitor, as thromboprophylaxis in patients following total knee replacement. J Thromb Haemost. 2007; 5(12): 2368-2375.

Sponsors, Associates, and Links

---

• Journal of Neurobiology and Genetics
  
  
• Medical Imaging and Nuclear Medicine
  
  
• Bacterial Genetics and Ecology
  
  
• Transactions on Cancer
  
  
• Journal of Biophysics and Ecology
  
  
• Journal of Animal Science and Veterinary
  
  
• Academic Journal of Biochemistry and Molecular Biology
  
  
• Transactions on Cell and Developmental Biology
  
  
• Rehabilitation Engineering & Assistive Technology
  
  
• Orthopaedics and Sports Medicine
  
  
• Hematology and Stem Cell
  
  
• Journal of Intelligent Informatics and Biomedical Engineering
  
  
• MEDS Basic Medicine
  
  
• MEDS Stomatology
  
  
• MEDS Public Health and Preventive Medicine
  
  
• MEDS Chinese Medicine
  
  
• Journal of Enzyme Engineering
  
  
• Advances in Industrial Pharmacy and Pharmaceutical Sciences
  
  
• Bacteriology and Microbiology
  
  
• Advances in Physiology and Pathophysiology
  
  
• Journal of Vision and Ophthalmology
  
  
• Frontiers of Obstetrics and Gynecology
  
  
• Digestive Disease and Diabetes
  
  
• Advances in Immunology and Vaccines
  
  
• Nanomedicine and Drug Delivery
  
  
• Cardiology and Vascular System
  
  
• Pediatrics and Child Health
  
  
• Journal of Reproductive Medicine and Contraception
  
  
• Journal of Respiratory and Lung Disease
  
  
• Journal of Bioinformatics and Biomedicine